Drug Repurposing and Repositioning - Workshop Summary
Note: Proceedings contain the opinion of the presenters, but do NOT reflect the conclusions of the Health and Medicine Division or the National Academies. Learn more about the differences between Reports and Proceedings.
Recent estimates suggest that, on average, it takes 10 years and at least $1 billion to bring a drug to market. Given this time and expense, pharmaceutical companies have become increasingly interested in finding new uses for existing drugs – a process referred to as drug repurposing or repositioning. In some cases where data have already been acquired, repurposing a drug can save time and money compared with developing a drug de novo. It has also been estimated that a larger percentage of repurposed drugs gain market approval as compared with drugs developed anew. Following the successful repurposing of an increasing number of previously shelved compounds, pharmaceutical companies are beginning to add repurposing projects to their research portfolios and the NIH is testing an award program aimed at identifying new uses for existing drugs.
Given the widespread interest in drug repurposing, the IOM Roundtable on Translating Genomic-Based Research for Health hosted a workshop on June 24, 2013, to assess the current landscape of drug repurposing activities in industry, academia, and government. This document summarizes the workshop.
For additional resources, such as the agenda and presentations, please visit the workshop page.